Professor Ian Smith
Ian E. Smith, MD, FRCP, FRCPE, is Professor of Cancer Medicine at The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom. His initial medical training was in Edinburgh and then he came to the Royal Marsden, London, for specialist training in cancer medicine. He also spent some time in Boston at the Dana-Farber Cancer Institute, Harvard. Over the years his principal clinical research interests have been in breast cancer, lung cancer, and in new drug development. He was involved in the early clinical development of several anticancer drugs that have subsequently proved effective in the clinic, including carboplatin and letrozole. In recent years he has become increasingly involved in neoadjuvant and short-duration preoperative therapies as a research approach towards individualised treatments for breast cancer. He is currently Chief Investigator or UK Principal Investigator for several international multicentre breast cancer trials involving in particular targeted therapies and aromatase inhibitors. He is also Chief Investigator for the UK POETIC trial, the largest of its kind in the world, aiming to individualise adjuvant therapy for patients with early breast cancer. He publishes extensively and is regularly invited to lecture at breast cancer conferences around the world. He was awarded the Susan G Komen for the Cure Brinker Award for Scientific Distinction at the 2009 San Antonio International Breast Cancer Conference, and in 2017 he was Visiting Professor at Ann Arbor University, Michigan. He has recently been awarded the William McGuire Memorial Award at the 2018 San Antonio Breast Cancer Conference.
Professor Smith was appointed first chairman of the UK Breast Trials Intergroup and has also been chairman of the British Breast Group. He was the Scientific Chairman of the Breast Section of 2012 ESMO, and he has also chaired several national professional bodies including the Association of Cancer Physicians, the Royal College of Physicians Specialist Advisory Committee for Medical Oncology, and the NCRI Lung Cancer Clinical Studies Group. He is was recently Co –Chairman of the ASCO Clinical Guidelines Group for Chemotherapy in Metastatic Breast Cancer, and in2014 he was appointed the first Chair of the recently formed national Breast Cancer Clinical Expert Group. He was a Patron of Breast Cancer Care, a large UK breast charity for patient support, until its recent amalgamation, and he is a Trustee of Breast Cancer Haven, another major patient support charity.